Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015

Eugenia Quiros-Roldan, Paola Magro, Elena Raffetti, Ilaria Izzo, Alberto Borghetti, Francesca Lombardi, Annalisa Saracino, Franco Maggiolo, Francesco Castelli, G. Carosi, Giulia Carosi, G. E. Paraninfo, C. Torti, Carlo Torti, Roberto Cauda, Simona Di Giambenedetto, M. Fabbiani, Manuela Colafigli, A. Scalzini, F. CastelnuovoI. El Hamad, F. Mazzotta, S. Locaputo, N. Marino, P. Pierotti, M. Di Pietro, Maria Luisa Di Pietro, C. Blè, F. Vichi, L. Sighinolfi, G. Angarano, N. Ladisa, L. Monno, P. Maggi, A. Pan, S. Costarelli, A. Gori, G. Lapadula, M. Puoti, P. Viale, V. Colangeli, M. Borderi

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Background: Triple-drug regimens are the gold standard for HIV therapy. Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) reducing regimens are used to decrease drugs toxicity, exposure and costs. Aim of our study was to evaluate trends of biochemical and inflammatory indices in patients switching to dual therapy (DT). Methods: We included patients that a) switched to a DT from 2007 to 2015 from a tenofovir/abacavir-based triple regimen b) previously maintained a triple and c) subsequently a dual regimen for 12 months with virological suppression. We retrieved data measured at 5 points (at the switch, 6 and 12 months before and after switch). We used platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and CD4/CD8 ratio as inflammatory indices. We assessed temporal trends of viro-immunological, biochemical and inflammatory parameters. Results: Overall, 364 and 65 patients switched from a tenofovir- and an abacavir-triple regimen, respectively. In the tenofovir-reducing group, creatinine clearance and lipids raised after the switch. There was a significant increase in both CD4+ cells and CD4/CD8. CD8+ cells rose after the switch, while opposite trend was found for PLR. In the abacavir-reducing group total lipids showed a decrease during the first 6 months after the switch and then stabilized. An increase of CD4+ and a decrease of CD8+ cells was observed during the study period, although not statistically significant. While CD4/CD8 remained stable after simplification, PLR decreased significantly after 6 months, then returning to baseline. CD8+ cells increased in the tenofovir-reducing group despite a viro-immunological response. Intriguingly, PLR decreased, maintaining this trend for 12 and 6 months after tenofovir and abacavir interruption respectively. Conclusions: Increased PLR has been linked to hypercholesterolemia and metabolic-syndrome, while high CD8+ cells count to increased risk of non-AIDS-related events regardless of CD4 T-cell recovery and to virological failure. Whether these findings may have clinical implications, and which role DT plays on the immune system and on inflammation should be further investigated.
Lingua originaleEnglish
pagine (da-a)1-11
Numero di pagine11
RivistaBMC Infectious Diseases
Stato di pubblicazionePubblicato - 2018


  • Adult
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Antiretroviral therapy
  • Atazanavir Sulfate
  • CD4-CD8 Ratio
  • Cohort Studies
  • Darunavir
  • Dideoxynucleosides
  • Dual-therapy
  • Female
  • HIV
  • HIV Infections
  • Humans
  • Inflammation
  • Italy
  • Male
  • Middle Aged
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors
  • Switch
  • Tenofovir
  • Treatment Outcome


Entra nei temi di ricerca di 'Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015'. Insieme formano una fingerprint unica.

Cita questo